Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2

By |2020-03-30T10:14:06-04:00January 2nd, 2019|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: , |

SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]